Abstract
Myasthenia gravis is an antibody-mediated autoimmune disease. Classically, antibodies against the acetylcholine receptor (AChR) cause inactivation and loss of acetylcholine receptors at the neuromuscular junction. Progress has been made not only in the identification of alternate autoantibodies in so called AChR-antibody negative patients but also concerning the diagnostic value of antibodies against striated muscle proteins. In this review, these advances in myasthenia gravis are summarized. Moreover, concerning therapy, the value of thymectomy is discussed and recent developments in immunotherapy ore reported.
| Translated title of the contribution | Advances in myasthenia gravis |
|---|---|
| Original language | German |
| Pages (from-to) | 127-131 |
| Number of pages | 5 |
| Journal | Nervenheilkunde |
| Volume | 23 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2004 |